-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

New Targets, New Data, New Guidelines: Assessing Treatment Options to Personalize Care in B-Cell Lymphomas

Sponsor: educational grants from Genmab US Inc; Karyopharm Therapeutics; and Pharmacyclics LLC
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Follicular Lymphoma, Biological, antibodies, CRS, Adult, Diseases, Lymphoma (any), Non-Biological, Mantle Cell Lymphoma, Therapies, CAR-Ts, Non-Hodgkin Lymphoma, checkpoint inhibitors, chemotherapy, Adverse Events, DLBCL, B-Cell Lymphoma, Biological Processes, DNA damage, Technology and Procedures, immunotherapy, Lymphoid Malignancies, Study Population, genomics, genetic profiling, Clinically relevant, transplantation, immune mechanism, flow cytometry, TKI, inflammation, mass cytometry, microenvironment, pathogenesis, pathways
Friday, December 4, 2020: 11:00 AM-2:00 PM
Chair:
Brad S. Kahl, MD, Washington University School of Medicine in St. Louis
Disclosures:
Kahl: Genentech: Consultancy; Pharmacyclics LLC: Consultancy; Roche Laboratories Inc: Consultancy; BeiGene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; AstraZeneca Pharmaceuticals LP: Consultancy, Membership on an entity's Board of Directors or advisory committees; Acerta: Consultancy, Research Funding; ADC Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy; Celgene Corporation: Consultancy.
Speakers:
Jason R. Westin, MD, MD Anderson , Thomas E. Witzig, MD, Mayo Clinic and Laurie H. Sehn, MD, MPH, BC Cancer Centre for Lymphoid Cancer, University of British Columbia
Disclosures:
Westin: 47 Inc: Consultancy; Curis: Consultancy; Janssen: Consultancy; Novartis: Consultancy; Genentech: Consultancy; Juno: Consultancy; Kite: Consultancy; MorphoSys: Consultancy; Unum: Consultancy. Witzig: MorphSys: Consultancy; AbbVie: Consultancy; Immune Design: Research Funding; Acerta: Research Funding; Spectrum: Consultancy; Celgene: Consultancy, Research Funding; Incyte: Consultancy; Karyopharm Therapeutics: Research Funding. Sehn: AbbVie: Consultancy, Honoraria; Apobiologix: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Genentech, Inc.: Consultancy, Honoraria, Research Funding; Acerta: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Lundbeck: Consultancy, Honoraria; Merck: Consultancy, Honoraria; MorphoSys: Consultancy, Honoraria; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria; Teva: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Chugai: Consultancy, Honoraria; TG therapeutics: Consultancy, Honoraria; Verastem Oncology: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Amgen: Consultancy, Honoraria.
The live portion of this curriculum will be presented as a 3-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting. Theactivity will feature a series of didactic presentations coupled with case presentations from prominent experts in the field that will be used as a starting point to discuss the latest data across forms of NHL.  The activity is designed to highlight and test participants on the most clinically relevant data in NHL, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets. The faculty panel will convene to share their own practice preferences (“How I treat”), perspectives on the clinical trial data and share clinical pearls from their own practices.  To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session with faculty throughout the activity to emphasize areas of educational need, highlighting areas of debate, and illustrating the application of new data in defined clinical situations.
See more of: Satellite Symposia